美国药品供应链安全法及其启示

摘要/Abstract

摘要： 2013年11月27日，美国国会通过的《药品供应链安全法》（Drug Supply Chain Security Act，DSCSA）明确规定，2014—2023年，美国将用10年时间建成覆盖全供应链的电子可互操作(interoperability）系统。规划以信息共享作为驱动核心，采取渐进式推进，实现对供应链中处方药的识别和追溯。法律明确了生产企业、再包装企业、药品经营批发企业、配送机构及第三方物流提供商在产品追溯、产品识别、产品验证与通知等方面的法律义务；建立了针对批发经营企业和第三方物流提供商的国家许可标准及其年报制度。电子可互操作系统的建立将实现处方药追溯的数字化，推动制药行业全流程的数字化和追溯相关技术新业态的发展，确保任何一方有能力避免有害药物进入供应链、侦测供应链中的有害药物并快速做出反应。美国的做法对我国正在推进的产品追溯工作具有一定借鉴意义。本文将系统介绍《药品供应链安全法》内容立法、实施中面临的挑战与启示，以期为我国开展相关工作、提升监管科学性提供参考和思路。

关键词: font-size:medium, ">药品供应链安全法；美国食品药品管理局；可互操作；药品追溯；启示

Abstract: The Drug Supply Chain Security Act(DSCSA）was enacted by U.S Congress on November 27, 2013.The DSCSA outlines steps over a-10 years, 2014-2023, to build an electronic, interoperability system to identify and trace certain prescription drugs as they are distributed in the United States.Driving by information sharing,the ACT clarifies the requirements for manufacturers, repackagers, wholesale distributors, dispensers, and third-party logistics providers in product tracing, identification, verification and notification, etc.Additionally, the DSCSA directs FDA to establish national licensure standards for wholesale distributors and third-party logistics providers, and requires these entities report licensure and other information to FDA annually.The electronic interoperability system will digitize product tracking and facilitate the new horizons in digitalization and trace-and-track all along the pharmaceutical industy to ensure the capability to prevent harmful drugs from entering the supply chain, detect harmful drugs if they do enter the supply chain, and enable rapid response when such drugs are found.This article overviews the DSCSA, the challenges and enlightenments in its implementation, in order to put reference to improve drug regulation scientifically.

Key words: Drug Supply Chain Security Act, Food and Drug Administration, Interoperability, Drug traceability, Enlightenment

中图分类号:

郑晓琼. 美国药品供应链安全法及其启示[J]. 中国医药导刊, 2020, 22(7): 500-505.

ZHENG Xiaoqiong. American Drug Supply Chain Security Act and its Enlightenment[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2020, 22(7): 500-505.

参考文献

[1]FDA. DSCSA Standards for the interoperable exchange of information for tracing of certain human， finished， prescription drugs： How to exchange product tracing information guidance for industry [EB/OL]. (2014-11-26) [2020-06-20]. https：//www. fda. gov/media/90548/download.
     [2]FDA. Standardization of data and documentation practices for product tracing guidance for industry DRAFT GUIDANCE[EB/OL]. (2018-2-28) [2020-06-20]. https：//www. fda. gov/media/111451/ download.
     [3]FDA. DSCSA Implementation：product tracing requirements —compliance policy guidance for industry[EB/OL]. (2014-12-23) [2020-06-20]. https：//www. fda. gov/media/90397/download.
     [4]FDA. DSCSA Implementation：Product Tracing Requirements for Dispensers—Compliance Policy(Revised) [EB/OL]. (2015-2-28) [2020-05-20]. https：//www. fda. gov/media/111451/download.
     [5]FDA. Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry DRAFT GUIDANCE. (2015-10-28) [2020-06-20]. https：//www. federalregister. gov/documents/2015/11/02/2015-27841/the-drug-supply-chain-security-act-implementation-product-tracing-requirements-for.
     [6]FDA. Product Identifier Requirements Under the Drug Supply Chain Security Act-Compliance Policy Guidance for Industry(Final Guidance) [EB/OL]. (2018-09-19) [2020-06-20]. https：//www. fda. gov/media/106198/download.
     [7]FDA. Product identifiers under the Drug Supply Chain Security Act-questions and qnswers(Draft Guidance) [EB/OL]. (2018-09-19) [2020-06-20]. https：//www. fda. gov/media/116304/download.
     [8]FDA. Grandfathering policy for packages and homogenous cases of product without a product identifier(Final Guidance) [EB/OL]. (2018-09-19) [2020-06-20]. https：//www. fda. gov/media/109591/download.
     [9]FDA. Verification systems under the Drug Supply Chain Security Act for certain prescription drugs(Draft Guidance) [EB/OL]. (2018-10-24) [2020-06-21]. https：//www.fda.gov/media/117950/download.
     [10]FDA. Drug Supply Chain Security Act implementation： identification of suspect product and notification guidance for industry(Guidance) [EB/OL]. (2016-12-08) [2020-06-21]. https：//www. fda. gov/media/88790/download.
     [11]FDA. Definitions of suspect product and illegitimate product for verification obligations under the Drug Supply Chain Security Act Guidance for Industry (Draft Guidance) [EB/OL]. (2018-02-28) [2020-06-21]. https：//www. fda.gov/media/111468/download.
     [12]FDA. Verification systems under the Drug Supply Chain Security Act for certain prescription drugs(Draft Guidance) [EB/OL]. (2018-10-24) [2020-06-21]. https：//www. fda. gov/media/117950/download.
     [13]FDA. Wholesale distributor verification requirement for saleable returned drug product—compliance policy guidance for industry(Final Guidance) [EB/OL]. (2019-09-23) [2020-06-21]. https：//www. fda. gov/media/117950/download.
     [14]FDA. Pharmaceutical distribution supply chain pilot projects； reopening of comment period； request for information(Notice) [EB/OL]. (2019-07-03) [2020-06-21]. https：//www. federalregister. gov/documents/2019/07/03/2019-14147/pharmaceutical-distribution-supply-chain-pilot-projects-reopening-of-comment-period-request-for.

[1]	廖娟, 覃姣玉, 王建超, 玉叶, 文彬, 邓鑫. “以平为期”治则在治疗新冠肺炎的应用[J]. 中国医药导刊, 2020, 22(9): 593-598.
[2]	刘可可, 吴倍华, 乔依白, 姚松梅, 奚斌, 陈萌蕾, 成文武. 晚期癌症患者的社区三阶梯疼痛治疗效果评价[J]. 中国医药导刊, 2020, 22(9): 599-603.
[3]	陈小兰, 朱琪. 中医在非酒精性脂肪性肝病治疗中的运用探讨[J]. 中国医药导刊, 2020, 22(9): 604-606.
[4]	李建垒, 曹向阳, 宋永伟. 保守治疗神经根型颈椎病的研究现状[J]. 中国医药导刊, 2020, 22(9): 607-610.
[5]	吴敏, 张洁. 颞下颌关节紊乱病的针灸推拿治疗研究进展[J]. 中国医药导刊, 2020, 22(9): 611-614.
[6]	程明荣, 戴德坚. 疏血通联合乌司他丁治疗高脂血症性胰腺炎对肠道激素和脂肪因子的影响[J]. 中国医药导刊, 2020, 22(9): 615-619.
[7]	王雪芳, 孙科佳, 彭红霞. 小儿肺咳颗粒联合阿奇霉素对喘息性支气管炎患儿肺功能及炎性因子的影响[J]. 中国医药导刊, 2020, 22(9): 620-623.
[8]	黄文忠, 曹红霞. 柴胡桂枝干姜汤临床应用与认识[J]. 中国医药导刊, 2020, 22(9): 624-626.
[9]	刘大锐, 李报春. 复合型右肺大细胞神经内分泌癌1例并文献复习[J]. 中国医药导刊, 2020, 22(9): 627-630.
[10]	王永军, 王舒颖, 张婷婷, 李晗怡, 李环. 11月龄全内脏反位支气管肺炎患儿病例报告1例[J]. 中国医药导刊, 2020, 22(9): 631-633.
[11]	王权, 杨珂璐, 王铸, 田金徽, 叶颖江, 王杉, 姜可伟. 单细胞测序技术的文献计量学研究及热点应用[J]. 中国医药导刊, 2020, 22(9): 634-641.
[12]	马静, 贾红政, 田亮玉, 李文茜, 贾永涛. 基于《临床用药须知》成方制剂中地黄及其炮制品的合理应用研究[J]. 中国医药导刊, 2020, 22(9): 642-645.
[13]	吕晓峰, 周鹏, 刘瑞霞, . 我院600例呼吸科住院患者抗菌药物使用情况分析[J]. 中国医药导刊, 2020, 22(9): 646-649.
[14]	杜林林, 梁毅, 周亚娴, 陶浪, 李韬, 李慧强. 以质量管理为突破的药品智慧监管新尝试——基于贵阳信息化案例分析[J]. 中国医药导刊, 2020, 22(9): 650-653.
[15]	李丽静, 黎运达, 包淑娟, 李木子, 赵锦, 刘新成. 区块链+特许药械追溯管理的实践与思考[J]. 中国医药导刊, 2020, 22(9): 654-658.

快速检索引用检索图表检索高级检索